Absorbable Hemostats Market 2025

Absorbable Hemostats Market Definition

Absorbable hemostats are medical devices designed to control bleeding during surgical procedures by promoting rapid coagulation at the site of injury or incision. These hemostats are bioabsorbable, meaning they are broken down and absorbed by the body over time, eliminating the need for removal after surgery. The absorbable hemostats market consists of sales, by entities (organizations, sole traders and partnerships), of absorbable hemostats that are commonly used in various surgical disciplines to ensure hemostasis, minimize blood loss and facilitate better surgical outcomes. The primary users of absorbable hemostats include surgeons, operating room personnel and healthcare professionals across a wide range of specialties. These devices are typically used intraoperatively in situations where mechanical means of bleeding control, such as sutures or clamps, are insufficient or impractical.

Absorbable Hemostats Market Segmentation

The absorbable hemostats market is segmented by type, by application and by end-user. By Type – The absorbable hemostats market is segmented by type into: a) Thrombin-Based Hemostats b) Oxidized Regenerated Cellulose-Based Hemostats c) Gelatin-Based Hemostats d) Collagen-Based Hemostats e) Other Types The gelatin-based hemostats market was the largest segment of the absorbable hemostats market segmented by type, accounting for 36.45% or $1,146.28 million of the total in 2024. Going forward, the oxidized regenerated cellulose-based hemostats segment is expected to be the fastest growing segment in the absorbable hemostats market segmented by type, at a CAGR of 8.94% during 2024-2029. By Application – The absorbable hemostats market is segmented by application into: a) Neurosurgery b) Orthopedic Surgery c) General Surgery d) Reconstructive Surgery e) Other Applications The general surgery market was the largest segment of the absorbable hemostats market segmented by application, accounting for 31.37% or $986.42 million of the total in 2024. Going forward, the orthopedic surgery segment is expected to be the fastest growing segment in the absorbable hemostats market segmented by application, at a CAGR of 9.11% during 2024-2029. By End User – The absorbable hemostats market is segmented by end user into: a) Hospitals And Clinics b) Ambulatory Surgical Centers d) Other End-Users The hospitals and clinics market was the largest segment of the absorbable hemostats market segmented by end-user, accounting for 66.31% or $2,085.33 million of the total in 2024. Going forward, the ambulatory surgical centers segment is expected to be the fastest growing segment in the absorbable hemostats market segmented by end-user, at a CAGR of 9.91% during 2024-2029. By Geography - The Absorbable hemostats market is segmented by geography into: o Asia Pacific • China • India • Japan • Australia • Indonesia • South Korea o North America • USA • Canada o South America • Brazil o Western Europe • France • Germany • UK • Italy • Spain o Eastern Europe • Russia o Middle East
o Africa North America was the largest region in the absorbable hemostats market, accounting for 39.64% or $1,246.70 million of the total in 2024. It was followed by Western Europe, Asia-Pacific and then the other regions. Going forward, the fastest-growing regions in the absorbable hemostats market will be Asia-Pacific and Eastern Europe where growth will be at CAGRs of 8.58% and 8.51% respectively. These will be followed by South America and Middle East where the markets are expected to grow at CAGRs of 8.41% and 8.18% respectively.

Absorbable Hemostats Market Drivers

The key drivers of the absorbable hemostats market include: Growing Prevalence of Chronic Diseases The growing prevalence of chronic diseases is expected to drive the growth of the absorbable hemostats market going forward. Patients with chronic diseases often face an increased risk of bleeding during surgical procedures, making effective bleeding management crucial to minimizing complications and improving outcomes. Hemostatic agents play a vital role in ensuring efficient hemostasis for these high-risk patients, driving their widespread use in clinical settings. For instance, in January 2024, according to the American Cancer Society, a US-based nonprofit cancer advocacy organization, the number of cancer cases increased to 2,001,140 compared to 1,958,310 in 2023, reflecting a growth of 2.19%. Additionally, in April 2024, according to the report by the International Agency for Research on Cancer (IARC), a France-based specialized agency of the World Health Organization (WHO) focused on cancer research, the annual number of new cancer cases will rise to 35 million by 2050. Therefore, growing chronic diseases will drive the growth of the absorbable hemostats market during the forecast period.

Absorbable Hemostats Market Restraints

The key restraints on the absorbable hemostats market include: Supply Chain Disruptions Supply chain disruptions are expected to restrict the growth of the absorbable hemostats market going forward. Hemostatic products rely on specific materials like biopolymers or clotting agents. These disruptions can lead to delays in production, shortages of raw materials and challenges in distribution, which may affect the availability of absorbable hemostats. Additionally, fluctuations in global trade, transportation issues and labor shortages can increase costs and lengthen delivery time to healthcare facilities, ultimately limiting market growth. For instance, in 2024, according to the Wall Street Journal, a US-based business- and economic-focused international daily newspaper, global supply chains will face disruptions at vital trade routes like the Panama Canal and the Suez Canal. Rising geopolitical tensions may further impact sourcing and distribution strategies, prompting countries and companies to reconsider established trade routes and networks developed over decades. Therefore, supply chain disruptions may hinder the growth of the absorbable hemostat market.

Absorbable Hemostats Market Trends

Major trends shaping the absorbable hemostats market include: Innovations in Absorbable Hemostats With Focus On Plant-Based Cellulose Matrix Solutions Major companies in the absorbable hemostats market are focusing on innovative wound care solutions that combine natural, biocompatible materials with advanced technological features such as plant-based cellulose matrix to enhance product efficacy, improve patient outcomes and gain a competitive edge in the growing demand for sustainable and effective healthcare solutions. A plant-based cellulose matrix in absorbable hemostats offers a natural, biocompatible solution that promotes rapid hemorrhage control, tissue regeneration and enhanced wound healing while being fully absorbable and biodegradable. For example, in April 2024, LifeScience PLUS, a US-based medical device manufacturer, launched DonorSeal, a 100% natural, plant-based cellulose matrix designed for donor site treatment. It rapidly controls hemorrhage, reduces blood loss and promotes wound healing by forming a translucent gel when it contacts blood, creating a moist wound environment essential for tissue regeneration. Key features include being fully absorbable, biodegradable, pH neutral, non-toxic and safe for all age groups, including patients on blood thinners, with no recurring bleeding or adhesion upon removal. Investment In Hemostatic Product Development Companies in the absorbable hemostats market are adopting various strategies, such as private placement funding, to secure funding for innovation and product development. Private placement funding refers to the process of raising capital by selling securities directly to a select group of investors, such as institutional investors or accredited individuals, rather than through a public offering. For instance, in April 2024, Medcura, Inc., a US-based medical device company that develops hemostatic products for surgical use, announced the successful closing of a private placement, raising US $22.4 million in convertible debt. The company plans to use the funds to accelerate the development of its lead product, LifeGel Absorbable Hemostatic Gel. Medcura aims to complete pre-clinical testing and file an Investigational Device Exemption (IDE) with the U.S. FDA (United States Food and Drug Administration) to support a global study focused on controlling bleeding in spinal surgery. Unlike current hemostatic agents, LifeGel is designed to avoid swelling and potential neurological complications, such as paralysis, in confined surgical spaces.

Opportunities And Recommendations In The Absorbable Hemostats Market

Opportunities – The top opportunities in the absorbable hemostats market segmented by type will arise in the gelatin-based hemostats segment, which will gain $477.75 million of global annual sales by 2029. The top opportunities in the absorbable hemostats market segmented by application will arise in the general surgery segment, which will gain $427.22 million of global annual sales by 2029. The top opportunities in the absorbable hemostats market segmented by end-user will arise in the hospitals and clinics segment, which will gain $888.35 million of global annual sales by 2029. The absorbable hemostats market size will gain the most in the USA at $479.43 million. Recommendations- To take advantage of the opportunities, The Business Research Company recommends the absorbable hemostats companies to focus on advancing biocompatible, sustainable hemostats, focus on leveraging private placement funding for innovation, focus on advancing biocompatible materials for minimally invasive procedures, focus on technological advancements in hemostatic powders, focus on advancing sealing patch technologies for rapid bleeding control, focus on developing bio adhesive hemostats with innovative materials, focus on thrombin-based hemostats to drive growth, expand in emerging markets, focus on expanding distribution channels for greater market reach, focus on developing competitive and flexible pricing strategies, focus on targeted marketing and educational campaigns, focus on collaborating with key opinion leaders and influencers, focus on orthopedic surgery to drive market growth and focus on hospitals and clinics to maximize growth.